Addendum
Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51
Report documents
-
Addendum
Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51
Dossier assessment
Indication:
Adjuvant treatment of patients with HR-positive, HER2-negative, node-positive early-stage breast cancer at high risk of recurrence
Result of dossier assessment:
Unchanged after addendum:
- Premenopausal women: hint of minor added benefit
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.
Project details
- Project no.
- A22-96
- Commission
- Commission awarded on 06.09.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed